TCR2, Inc. is a discovery stage pharmaceutical company focused on the development of biological drugs and engineering T cells for cancer therapy.
TCR2 Therapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/tcr2-inc-” connections=”true” suffix=””]
TCR2s proprietary multi-format TRuC_ platform that developes novel class of engineered (TCR) fusion constructs to reprograms the natural TCR complex to elicit rapid killing of cancer cells with long persistence and low cytokine release.
TRuC_ platform, enables the creation of a novel first-in-class approach to express defined TCR alpha/beta chains. The company has demonstrated superior activWity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead solid tumor program TC-210 targeting mesothelin into the clinic in 2018.
In Mar 2018, TCR2 raised $125 Mn USD in Series B funding round; co-led by 6 Dimensions Capital and Curative Ventures with participation from new investors including Redmile Group, ArrowMark Partners, Hillhouse Capital Group, MiraeAsset Financial Group, Syno Capital, Haitong International Securities, Lucion Group, Sirona Capital, Alexandria Venture Investments and entities affiliated with Leerink Partners. They were joined by all the existing investors_MPM Capital, F2 Ventures and Cathay Fortune Capital Investment.